{"id":"https://openalex.org/W3198793301","doi":"https://doi.org/10.3389/fphar.2021.723038","title":"Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120","display_name":"Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120","publication_year":2021,"publication_date":"2021-08-11","ids":{"openalex":"https://openalex.org/W3198793301","doi":"https://doi.org/10.3389/fphar.2021.723038","mag":"3198793301","pmid":"https://pubmed.ncbi.nlm.nih.gov/34456733","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8386121"},"language":"en","primary_location":{"id":"doi:10.3389/fphar.2021.723038","doi":"https://doi.org/10.3389/fphar.2021.723038","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2021.723038","pdf_url":"https://www.frontiersin.org/articles/10.3389/fphar.2021.723038/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/articles/10.3389/fphar.2021.723038/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018062236","display_name":"Andrey V. Kulikov","orcid":"https://orcid.org/0000-0002-1784-2285","observed_orcids":["https://orcid.org/0000-0002-1784-2285"]},"institutions":[{"id":"https://openalex.org/I4210097816","display_name":"R-Pharm (Russia)","ror":"https://ror.org/00veetk09","country_code":"RU","type":"company","lineage":["https://openalex.org/I4210097816"]}],"countries":["RU"],"is_corresponding":true,"raw_author_name":"Andrey Kulikov","raw_affiliation_strings":["JSC R-Pharm, Moscow, Russia","JSC R-Pharm, Russia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"JSC R-Pharm, Moscow, Russia","institution_ids":["https://openalex.org/I4210097816"]},{"raw_affiliation_string":"JSC R-Pharm, Russia","institution_ids":["https://openalex.org/I4210097816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064093803","display_name":"Elena V. Shipaeva","orcid":"https://orcid.org/0000-0002-5953-984X","observed_orcids":["https://orcid.org/0000-0002-5953-984X"]},"institutions":[{"id":"https://openalex.org/I4210097816","display_name":"R-Pharm (Russia)","ror":"https://ror.org/00veetk09","country_code":"RU","type":"company","lineage":["https://openalex.org/I4210097816"]}],"countries":["RU"],"is_corresponding":false,"raw_author_name":"Elena Shipaeva","raw_affiliation_strings":["JSC R-Pharm, Moscow, Russia","JSC R-Pharm, Russia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"JSC R-Pharm, Moscow, Russia","institution_ids":["https://openalex.org/I4210097816"]},{"raw_affiliation_string":"JSC R-Pharm, Russia","institution_ids":["https://openalex.org/I4210097816"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Anastasia Dmitrieva","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210097816","display_name":"R-Pharm (Russia)","ror":"https://ror.org/00veetk09","country_code":"RU","type":"company","lineage":["https://openalex.org/I4210097816"]}],"countries":["RU"],"is_corresponding":false,"raw_author_name":"Anastasia Dmitrieva","raw_affiliation_strings":["JSC R-Pharm, Moscow, Russia","JSC R-Pharm, Russia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"JSC R-Pharm, Moscow, Russia","institution_ids":["https://openalex.org/I4210097816"]},{"raw_affiliation_string":"JSC R-Pharm, Russia","institution_ids":["https://openalex.org/I4210097816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020100529","display_name":"Vera Batrak","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210097816","display_name":"R-Pharm (Russia)","ror":"https://ror.org/00veetk09","country_code":"RU","type":"company","lineage":["https://openalex.org/I4210097816"]}],"countries":["RU"],"is_corresponding":false,"raw_author_name":"Vera Batrak","raw_affiliation_strings":["JSC R-Pharm, Moscow, Russia","JSC R-Pharm, Russia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"JSC R-Pharm, Moscow, Russia","institution_ids":["https://openalex.org/I4210097816"]},{"raw_affiliation_string":"JSC R-Pharm, Russia","institution_ids":["https://openalex.org/I4210097816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029080331","display_name":"Georgy Shipunov","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210097816","display_name":"R-Pharm (Russia)","ror":"https://ror.org/00veetk09","country_code":"RU","type":"company","lineage":["https://openalex.org/I4210097816"]}],"countries":["RU"],"is_corresponding":false,"raw_author_name":"Georgy Shipunov","raw_affiliation_strings":["JSC R-Pharm, Moscow, Russia","JSC R-Pharm, Russia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"JSC R-Pharm, Moscow, Russia","institution_ids":["https://openalex.org/I4210097816"]},{"raw_affiliation_string":"JSC R-Pharm, Russia","institution_ids":["https://openalex.org/I4210097816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091779052","display_name":"Colin P. Guy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210166171","display_name":"Covance (United Kingdom)","ror":"https://ror.org/059vag305","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210166171","https://openalex.org/I60638368"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Colin Guy","raw_affiliation_strings":["Covance Laboratories Ltd, Harrogate, United Kingdom","Covance Laboratories Ltd, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Covance Laboratories Ltd, Harrogate, United Kingdom","institution_ids":["https://openalex.org/I4210166171"]},{"raw_affiliation_string":"Covance Laboratories Ltd, United Kingdom","institution_ids":["https://openalex.org/I4210166171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071284216","display_name":"J. Stanley Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210166171","display_name":"Covance (United Kingdom)","ror":"https://ror.org/059vag305","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210166171","https://openalex.org/I60638368"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jill Smith","raw_affiliation_strings":["Covance Laboratories Ltd, Harrogate, United Kingdom","Covance Laboratories Ltd, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Covance Laboratories Ltd, Harrogate, United Kingdom","institution_ids":["https://openalex.org/I4210166171"]},{"raw_affiliation_string":"Covance Laboratories Ltd, United Kingdom","institution_ids":["https://openalex.org/I4210166171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100439276","display_name":"Ran Zhang","orcid":"https://orcid.org/0000-0001-5160-3491","observed_orcids":["https://orcid.org/0000-0001-5160-3491"]},"institutions":[{"id":"https://openalex.org/I4210166171","display_name":"Covance (United Kingdom)","ror":"https://ror.org/059vag305","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210166171","https://openalex.org/I60638368"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ran Zhang","raw_affiliation_strings":["Covance Laboratories Ltd, Harrogate, United Kingdom","Covance Laboratories Ltd, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Covance Laboratories Ltd, Harrogate, United Kingdom","institution_ids":["https://openalex.org/I4210166171"]},{"raw_affiliation_string":"Covance Laboratories Ltd, United Kingdom","institution_ids":["https://openalex.org/I4210166171"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Michael Zhang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Zhang","raw_affiliation_strings":["PharmaLegacy, Shanghai, China","PharmaLegacy, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PharmaLegacy, Shanghai, China","institution_ids":[]},{"raw_affiliation_string":"PharmaLegacy, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026793050","display_name":"Jeff Duan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeff Duan","raw_affiliation_strings":["PharmaLegacy, Shanghai, China","PharmaLegacy, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PharmaLegacy, Shanghai, China","institution_ids":[]},{"raw_affiliation_string":"PharmaLegacy, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068157305","display_name":"Anton Chestukhin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anton Chestukhin","raw_affiliation_strings":["Affinity Molecules, LLC, Richmond, VA, United States","Affinity Molecules, LLC, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Affinity Molecules, LLC, Richmond, VA, United States","institution_ids":[]},{"raw_affiliation_string":"Affinity Molecules, LLC, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019472034","display_name":"Sergei F. Barbashov","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sergei Barbashov","raw_affiliation_strings":["R-Pharm Overseas Inc, San Diego, CA, United States","R-Pharm Overseas Inc, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"R-Pharm Overseas Inc, San Diego, CA, United States","institution_ids":[]},{"raw_affiliation_string":"R-Pharm Overseas Inc, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034550383","display_name":"Samsonov MIu","orcid":"https://orcid.org/0000-0003-2685-1623","observed_orcids":["https://orcid.org/0000-0003-2685-1623"]},"institutions":[{"id":"https://openalex.org/I4210097816","display_name":"R-Pharm (Russia)","ror":"https://ror.org/00veetk09","country_code":"RU","type":"company","lineage":["https://openalex.org/I4210097816"]}],"countries":["RU"],"is_corresponding":false,"raw_author_name":"Mikhail Samsonov","raw_affiliation_strings":["JSC R-Pharm, Moscow, Russia","JSC R-Pharm, Russia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"JSC R-Pharm, Moscow, Russia","institution_ids":["https://openalex.org/I4210097816"]},{"raw_affiliation_string":"JSC R-Pharm, Russia","institution_ids":["https://openalex.org/I4210097816"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5084379384","display_name":"Yan Lavrovsky","orcid":"https://orcid.org/0009-0008-8935-1507","observed_orcids":["https://orcid.org/0009-0008-8935-1507"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yan Lavrovsky","raw_affiliation_strings":["R-Pharm Overseas Inc, San Diego, CA, United States","R-Pharm Overseas Inc, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"R-Pharm Overseas Inc, San Diego, CA, United States","institution_ids":[]},{"raw_affiliation_string":"R-Pharm Overseas Inc, United States","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5018062236"],"corresponding_institution_ids":["https://openalex.org/I4210097816"],"apc_list":{"value":2950,"currency":"USD","value_usd":2950},"apc_paid":{"value":2950,"currency":"USD","value_usd":2950},"fwci":0.4069,"has_fulltext":true,"cited_by_count":9,"citation_normalized_percentile":{"value":0.60987299,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"12","issue":null,"first_page":"723038","last_page":"723038"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-pd-l1-monoclonal-antibody","display_name":"anti-PD-L1 monoclonal antibody","score":0.9670000076293945},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.7149999737739563},{"id":"https://openalex.org/keywords/antibody-affinity","display_name":"antibody affinity","score":0.6650000214576721},{"id":"https://openalex.org/keywords/cross-species-reactivity","display_name":"cross-species reactivity","score":0.7799999713897705},{"id":"https://openalex.org/keywords/t-cell-activation","display_name":"T cell activation","score":0.7789999842643738},{"id":"https://openalex.org/keywords/pd-1-pd-l1-interaction","display_name":"PD-1/PD-L1 interaction","score":0.921999990940094},{"id":"https://openalex.org/keywords/lung-cancer-xenografts","display_name":"lung cancer xenografts","score":0.8500000238418579},{"id":"https://openalex.org/keywords/humanized-mouse-model","display_name":"humanized mice","score":0.6129999756813049},{"id":"https://openalex.org/keywords/toxicokinetics","display_name":"toxicokinetics","score":0.8709999918937683},{"id":"https://openalex.org/keywords/dose-range-finding","display_name":"dose range finding","score":0.6230000257492065},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.6800000071525574}],"concepts":[{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6208901405334473},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.6123644709587097},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.49927377700805664},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4687255620956421},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.42775362730026245},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4160999655723572},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.40481048822402954},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.25540244579315186},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.15805897116661072},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.10829952359199524},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.3389/fphar.2021.723038","doi":"https://doi.org/10.3389/fphar.2021.723038","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2021.723038","pdf_url":"https://www.frontiersin.org/articles/10.3389/fphar.2021.723038/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8386121","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8386121","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Pharmacol","raw_type":"Text"},{"id":"pmid:34456733","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34456733","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in pharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:5dbb2234d8f24276a1a0965cf6215e2e","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/5dbb2234d8f24276a1a0965cf6215e2e","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Pharmacology, Vol 12 (2021)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fphar.2021.723038","doi":"https://doi.org/10.3389/fphar.2021.723038","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2021.723038","pdf_url":"https://www.frontiersin.org/articles/10.3389/fphar.2021.723038/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3198793301.pdf","grobid_xml":"https://content.openalex.org/works/W3198793301.grobid-xml"},"referenced_works_count":26,"referenced_works":["https://openalex.org/W1893566975","https://openalex.org/W1994993231","https://openalex.org/W2016732129","https://openalex.org/W2028376975","https://openalex.org/W2038807218","https://openalex.org/W2082878575","https://openalex.org/W2099609050","https://openalex.org/W2103164876","https://openalex.org/W2123176392","https://openalex.org/W2143880498","https://openalex.org/W2144547008","https://openalex.org/W2155464214","https://openalex.org/W2509486054","https://openalex.org/W2619512349","https://openalex.org/W2756648224","https://openalex.org/W2894234470","https://openalex.org/W2900174742","https://openalex.org/W2925030036","https://openalex.org/W2967658120","https://openalex.org/W2998269674","https://openalex.org/W3001651930","https://openalex.org/W3005376436","https://openalex.org/W3015178699","https://openalex.org/W3045663587","https://openalex.org/W4206361783","https://openalex.org/W6775391015"],"related_works":["https://openalex.org/W2236929991","https://openalex.org/W4402131488","https://openalex.org/W3006973452","https://openalex.org/W2885709677","https://openalex.org/W6958301293","https://openalex.org/W3029868931","https://openalex.org/W2740703372","https://openalex.org/W4411198573","https://openalex.org/W4378882731","https://openalex.org/W2890811159"],"abstract_inverted_index":{"RPH-120":[0,27,52,90,122,152,191,202],"is":[1,53,203],"a":[2,138,204],"novel":[3],"fully":[4],"human":[5,33,58,72],"anti-PD-L1":[6,206],"IgG1":[7],"monoclonal":[8],"antibody":[9],"with":[10],"specifically":[11],"designed":[12],"Asn300Ala":[13],"mutation":[14],"in":[15,104,109,149,194,197],"Fc":[16],"fragment.":[17],"Surface":[18],"plasmon":[19],"resonance":[20],"assay":[21],"showed":[22,68],"that":[23,51,89,134],"affinity":[24,41],"of":[25,32,71,135,178],"the":[26,29,43],"to":[28,42,55,57,93,133,180],"dimeric":[30],"form":[31],"PD-L1-Fc":[34],"fusion":[35],"protein":[36],"was":[37,79,91,102,131,153,172,183],"much":[38],"higher":[39],"than":[40],"monomeric":[44],"His-tagged":[45],"PD-L1.":[46,64],"Further":[47],"binding":[48],"studies":[49],"demonstrated":[50,123,173],"able":[54,92],"bind":[56],"and":[59,73,119,128,143,174,196,200],"monkey":[60],"but":[61],"not":[62],"mouse":[63],"Tissue":[65],"cross-reactivity":[66],"study":[67,87,147],"good":[69],"comparability":[70],"Cynomolgus":[74,150],"monkeys":[75],"tissue":[76],"staining.":[77],"Bioactivity":[78],"assessed":[80],"using":[81],"mixed":[82],"lymphocyte":[83],"reaction":[84],"assay.":[85],"This":[86],"revealed":[88,192],"activate":[94],"T":[95],"cells":[96],"preventing":[97],"PD1/PD-L1":[98],"interaction.":[99],"Antitumor":[100],"efficacy":[101],"analyzed":[103],"HCC-827":[105],"lung":[106],"cancer":[107,210],"xenografts":[108],"humanized":[110],"CD34+":[111],"mice":[112],"at":[113,176],"three":[114],"dosage":[115],"levels:":[116],"20,":[117],"80,":[118],"200":[120,181],"mg/kg.":[121],"significant":[124],"tumor":[125],"growth":[126],"inhibition,":[127],"this":[129],"inhibition":[130],"comparable":[132],"atezolizumab.":[136],"In":[137,189],"single":[139],"dose":[140,144],"toxicity,":[141],"toxicokinetic":[142,170],"range":[145],"finding":[146],"performed":[148],"monkeys,":[151],"administered":[154],"via":[155],"intravenous":[156],"(IV)":[157],"bolus":[158],"or":[159],"60-min":[160],"IV":[161],"infusion,":[162],"followed":[163],"by":[164,186],"8-weeks":[165],"recovery":[166],"period.":[167],"An":[168],"acceptable":[169],"profile":[171],"administration":[175],"doses":[177],"up":[179],"mg/kg":[182],"well":[184],"tolerated":[185],"all":[187],"animals.":[188],"conclusion,":[190],"promising":[193],"vitro":[195],"vivo":[198],"activity":[199],"safety.":[201],"potent":[205],"drug":[207],"candidate":[208],"for":[209],"immunotherapy.":[211]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2022,"cited_by_count":1}],"updated_date":"2026-10-28T10:33:24.094632","created_date":"2021-09-13T00:00:00"}